BioSpace News Archive

Kodiak Sciences Inc., a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced that management will present at the following upcoming virtual investor conferences

NANOBIOTIX: Preclinical Data Presented at First AACR Virtual Special Conference on Radiation Science and Medicine Showed NBTXR3 Combo Overcomes Anti-PD-1 Resistance, Promotes Strong Abscopal Effect and Long-Term Anti-Cancer Memory

ERS Genomics Limited, which was formed to provide broad access to foundational CRISPR/Cas9 intellectual property today announced the signing of a license agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka).

Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference.

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, 2021.

Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its fourth quarter and full year 2020 financial results on Tuesday, March 16, 2021, after the market close.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the randomized, double-blind, placebo-controlled Phase 2b CAPTIVATE clinical trial evaluating three doses of olorinab, a novel, oral, peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), in participants with abdominal pain due to Irritable Bowel Syndrome (IBS).

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of the QIAcube Connect MDx, a flexible platform for automated sample processing that will now be available to molecular diagnostic laboratories in the U.S. and Canada, the European Union and other markets worldwide.

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing of its previously announced underwritten public offering of 1,562,500 common shares of Edesa, at a price to the public of $6.40 per share, less underwriting discounts and commissions. The gross proceeds were $10.0 million, before deducting underwriting discounts and commissions and other offering

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the H.C. Wainwright Global Life Sciences Conference, which will be held virtually on March 9-10, 2021.